# DESCRIPTION

## BACKGROUND OF THE INVENTION

- motivate cancer vaccines

## SUMMARY OF THE INVENTION

- introduce recombinant MVA vector
- describe TAA and matrix protein sequences
- specify insertion sites for sequences
- detail promoters and optimization
- describe pharmaceutical composition
- outline administration methods
- summarize aspects of invention

## DETAILED DESCRIPTION OF THE INVENTION

- introduce compositions and methods for producing an immune response to a tumor associated antigen (TAA)

### I. Definitions

- define antigen
- define binding antibody
- define cancer
- define cell-mediated immune response
- define conservative amino acid substitution
- define deletion
- define Ebola virus
- define fragment
- define growth inhibitory amount

### II. Tumor Associated Antigens

- describe tumor associated antigens and their use in inducing an immune response

### III. Recombinant Viral Vectors

- introduce MVA vector
- describe MVA vector construction
- discuss MVA vector advantages
- detail MVA vector design and manufacture
- describe gene inserts and promoters
- provide examples of TAA sequences
- discuss vector expression and regulation
- describe vaccine composition and administration
- summarize vector optimization and host cells

### IV. Pharmaceutical Composition

- formulate recombinant viral vectors as pharmaceutical compositions
- describe vaccine composition with one or more TAA sequences
- list various adjuvants and their formulations
- outline controlled or extended release formulations

### V. Combination with Checkpoint Inhibitors and Chemotherapy

- describe administering standard of care therapy with vector compositions
- outline combination with checkpoint inhibitors to activate T-cells
- list FDA-approved antibodies for combination therapy
- describe administering vector compositions with adjuvant chemotherapy
- list various chemotherapeutic agents for combination therapy

### VI. Method of Use

- define method of inducing immune response
- describe treatment of neoplasm
- outline treatment of proliferative disorder
- detail immune response
- administer composition
- outline method of use
- describe administration intervals
- motivate monitoring treatment progress
- describe biological activity monitoring
- describe immune response monitoring
- describe clinical response monitoring
- outline dosage determination
- describe effective amount determination
- outline indications for treatment
- describe administration routes
- outline vaccination protocols

## EXAMPLES

### Example 1. MVA Vaccine Vectors

- describe MVA vaccine vectors

### Example 2. Sequence Optimization

- optimize MUC1 sequences

### Example 3: MVA Vaccine Construction and In Vitro Evaluation for Hypoglycosylated Forms of MUC1

- construct MVA vaccine
- evaluate vaccine in vitro

### Example 4: Targeted Diminution of O-Linked Glycosylation of Muc1

- introduce Muc1 glycosylation pathway
- describe T synthase and COSMC genes
- outline methods for siRNA design and gene knockdown
- describe cell lines and transient expression constructs
- outline experimental plan for shRNA knockdown and ectopic expression
- discuss potential future directions and modifications

